National Hospital Organization Kanazawa Medical Center

Kanazawa 920-8650

4 studies enrolling now · 10 studies all time

What they study most

Atherosclerotic Cardiovascular Disease (ASCVD), Colitis, Ulcerative, Elevated Lp(a), End Stage Kidney Disease, Influenza, Peripheral Arterial Disease, Respiratory Syncytial Virus Infections, Respiratory Syncytial Viruses, Ulcerative Colitis, Ulcerative Colitis Chronic

Studies at this site

• Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease — Recruiting now
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection — Stopped early
• Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza — Completed
• A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus — Stopped early